Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
- Authors
- Kim, Woohyeun; Yoon, Yeonyee E.; Shin, Sung-Hee; Bae, Jang-Whan; Hong, Bum-Kee; Hong, Soon Jun; Sung, Ki Chul; Han, Seung Hwan; Kim, Weon; Rhee, Moo-Yong; Kim, Sang-Hyun; Lee, Sang Eun; Hyon, Min Su; Hwang, Gyo-Seung; Son, Jang Won; Kim, Jang-Young; Kim, Min Kyu; Kim, Sang Wook; Park, Jae-Hyeong; Shin, Jin Ho; Park, Chang Gyu
- Issue Date
- Jun-2018
- Publisher
- ELSEVIER
- Keywords
- cardiovascular diseases; combination therapy; ezetimibe; LDL-C; rosuvastatin
- Citation
- CLINICAL THERAPEUTICS, v.40, no.6, pp 993 - 1013
- Pages
- 21
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- CLINICAL THERAPEUTICS
- Volume
- 40
- Number
- 6
- Start Page
- 993
- End Page
- 1013
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3503
- DOI
- 10.1016/j.clinthera.2018.04.015
- ISSN
- 0149-2918
1879-114X
- Abstract
- Purpose: The aim of this study was to evaluate the safety and efficacy of combination treatment of rosuvastatin with ezetimibe in patients with primary hypercholesterolemia. Methods: This multicenter, randomized, double-blind study comprised a main study and an extension study. In the main study, the efficacy and safety of a combination of rosuvastatin (5, 10, and 20 mg) with ezetimibe (10 mg) were compared with those of rosuvastatin (5, 10, and 20 mg) alone. The subjects who achieved the National Cholesterol Education Program Adult Treatment Panel III LDL-C goal in the main study and agreed to a further study were enrolled for the extension study. In the extension study, ezetimibe 10 mg was also administered to subjects who had received rosuvastatin (5, 10, and 20 mg) alone in the main study, and the same treatment was continued for subjects who had received a combination of rosuvastatin with ezetimibe in the main study. Findings: At the end of the main study (week 8), LDL-C levels were significantly lower in subjects receiving combination therapy than in those receiving rosuvastatin monotherapy. Other lipid profiles also significantly improved in the combination therapy group. These improvements continued in the extension study. The combination therapy of rosuvastatin and ezetimibe was generally well tolerated. At the end of the main study, more subjects achieved the National Cholesterol Education Program Adult Treatment Panel III LDL-C goal in the combination therapy group than in the monotherapy group. The increased dosage of rosuvastatin was also well tolerated in the combination treatment. (C) 2018 Published by Elsevier HS Journals, Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Cardiology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.